GGrantIndex
Sort

24,576 grants matching microbiome

Investigating the Genetic, Cellular, and Metabolic Events Important for Urothelial Homeostasis and Response to Injury

$1,200,000
Cathy L Mendelsohn · Columbia University Health Sciences · U54 · FY2024 · DK

Investigating the Genetic, Cellular, and Metabolic Events Important for Urothelial Homeostasis and Response to Injury

$1,200,000
Cathy L Mendelsohn · Columbia University Health Sciences · U54 · FY2025 · DK

Investigating the Genetic, Cellular, and Metabolic Events Important for Urothelial Homeostasis and Response to Urinary Tract Infection

$1,200,000
Cathy L Mendelsohn · Columbia University Health Sciences · U54 · FY2019 · DK

Investigating the Genetic, Cellular, and Metabolic Events Important for Urothelial Homeostasis and Response to Injury

$1,200,000
Cathy L Mendelsohn · Columbia University Health Sciences · U54 · FY2021 · DK

TO EFFECTIVELY MITIGATE ANTIMICROBIAL RESISTANCE IN THE AGRICULTURAL ECOSYSTEM, THERE IS AN INCREASING PRESSURE TO REDUCE AND ELIMINATE THE USE OF IN-FEED ANTIBIOTICS FOR GROWTH PROMOTION AND DISEASE CONTROL IN FOOD ANIMALS. HOWEVER, LIMITING ANTIBIOTICS COULD COMPROMISE PRODUCTION EFFICIENCY AND ANIMAL HEALTH. THUS, DEVELOPING EFFECTIVE ALTERNATIVES TO ANTIBIOTICS IS URGENTLY NEEDED. BUILDING UPON OUR ACCUMULATIVE RESEARCH EFFORTS ON FUNCTIONAL MICROBIOME AS WELL AS MODULATION OF HOST INNATE IMMUNITY, WE HAVE DEVELOPED TWO TYPES OF INNOVATIVE SMALL MOLECULES, NAMELY BILE SALT HYDROLASE INHIBITORS AND HOST DEFENSE PEPTIDE-INDUCING COMPOUNDS, AS ALTERNATIVES TO ANTIBIOTICS FOR GROWTH PROMOTION AND DISEASE CONTROL IN POULTRY. IN THIS PROPOSAL, WE PROPOSE TO USE INNOVATIVE AND COST-EFFECTIVE ENCAPSULATION TECHNOLOGIES TO FURTHER IMPROVE THE EFFICACY OF THESE NATURAL COMPOUNDS FOR COMMERCIAL APPLICATIONS. WE ALSO WILL DEVELOP EFFECTIVE EXTENSION AND EDUCATION PROGRAMS WHICH ARE HIGHLY INTEGRATED WITH RESEARCH TO ENCOURAGE ADOPTION OF INNOVATIVE NON-ANTIBIOTIC STRATEGIES. THE PROPOSED WORK WAS DEVELOPED WITH SIGNIFICANT INPUTS FROM STAKEHOLDERS AND RECEIVED ENTHUSIASTIC SUPPORT FROM THE INDUSTRY. THIS MULTI-DISCIPLINARY PROJECT WILL BE CONDUCTED BY A HIGHLY QUALIFIED MULTI-INSTITUTIONAL TEAM WITH MAJOR PARTICIPANTS FROM TWO USDA EPSCOR INSTITUTIONS. THE OUTCOMES OF THE PROJECT WILL LEAD TO THE DEVELOPMENT OF TWO INNOVATIVE NON-ANTIBIOTIC FEEDING TECHNOLOGIES FOR IMMEDIATE ADOPTION AND COMMERCIALIZATION IN POULTRY AND POSSIBLY OTHER LIVESTOCK, THUS MITIGATING ANTIMICROBIAL RESISTANCE ACROSS THE FOOD CHAIN.

$1,200,000
University Of Tennessee · · FY2018 · National Institute of Food and Agriculture

Investigating the Genetic, Cellular, and Metabolic Events Important for Urothelial Homeostasis and Response to Injury

$1,199,999
Cathy L Mendelsohn · Columbia University Health Sciences · U54 · FY2022 · DK

The Roles of Heterogeneity, Mechanics, and the Environment in Biofilm Growth and Emergent Properties

$1,199,999
Howard A Stone · Princeton University · · FY2019 · BIO

The Resource of the MMRRC at UC Davis

$1,199,680
Kc Kent Lloyd · University Of California At Davis · U42 · FY2024 · OD

Mechanisms of Chronic Inflammation in Periodontitis

$1,199,034
Niki Moutsopoulos · National Institute Of Dental & Craniofacial Research · ZIA · FY2018 · DE

Oral Microbial and Immunological Characterization of Patients with Immune Dysfun

$1,199,034
Niki Moutsopoulos · National Institute Of Dental & Craniofacial Research · ZIA · FY2018 · DE

The Resource of the MMRRC at UC Davis

$1,198,813
Kc Kent Lloyd · University Of California At Davis · U42 · FY2022 · OD

Orbitrap Eclipse Tribrid Mass Spectrometer as a Regional Resource

$1,198,520
Fuming Zhang · Rensselaer Polytechnic Institute · S10 · FY2023 · OD

1/3: The Chicago Cancer Health Equity Collaborative (ChicagoCHEC)

$1,198,428
Melissa A. Simon · Northwestern University At Chicago · U54 · FY2021 · CA

Therapeutic targets in African-American youth with type 2 diabetes

$1,198,228
Stephanie Therese Chung · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK

Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda

$1,197,862
Matthew G Dorsey · University Of California, San Francisco · U01 · FY2021 · AI

A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)

$1,197,275
Lorin K Johnson · Glycyx Mor, Inc. · R44 · FY2025 · CA

California NeuroAIDS Tissue Network

$1,197,215
David J Moore · University Of California, San Diego · U24 · FY2019 · MH

Protein Modifications Involved in Cell Signaling

$1,196,889
Aleksandra Nita-Lazar · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Disappearing gastrointestinal microbiota in epidemic obesity.

$1,196,335
Martin J Blaser · New York University School Of Medicine · R01 · FY2015 · DK

1/3: The Chicago Cancer Health Equity Collaborative (ChicagoCHEC)

$1,195,987
Melissa A. Simon · Northwestern University At Chicago · U54 · FY2024 · CA

Genome-Wide Association Study of Early Childhood Caries

$1,195,877
Kimon Divaris · Univ Of North Carolina Chapel Hill · U01 · FY2019 · DE

1/3: The Chicago Cancer Health Equity Collaborative (ChicagoCHEC)

$1,195,558
Melissa A. Simon · Northwestern University At Chicago · U54 · FY2023 · CA

The Role of Human Milk in Infant Nutrition and Health

$1,195,481
Ardythe L. Morrow · Cincinnati Childrens Hosp Med Ctr · P01 · FY2009 · HD

Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda

$1,194,675
Matthew G Dorsey · University Of California, San Francisco · U01 · FY2020 · AI

Evaluating timing and extent of prenatal exposure to dolutegravir and early childhood outcomes

$1,194,553
Jillian Pintye · University Of Washington · P01 · FY2022 · HD